

High Conviction Bets

Nandan Chakraborty

Sachchidanand Shukla

MD – Institutional Equity Research nandan@enam.com; (+91 22 6754 7601) Sr VP & Economist sachins@enam.com; (+91 22 6754 7648) Source: http://www.123rf.com

August 11, 2011

Summary



- Market Outlook: We are today in a sweet-spot rally, based on the combination of weak global growth + measures to avoid liquidity collapse. This will last till the next QE – which can again jerk markets down, till policy action by the Indian Govt or the relative growth/ fisc/ valuation of India again stand out
- Till then, select picks in interest-rate sensitives (Banks) and domestic consumption to outperform v/s expensive defensives (FMCG) and global-vulnerables (Metals). Policy cues to drive other sectors
- What has prompted this change in outlook?
 - Developed world: The FOMC has signaled a focus on growth and employment generation by committing to low interest rates and a preparedness to bring in QE3 as may be required in future. A tiny QE may be good for global liquidity and growth (and hence India), but anything more could buoy commodities, hurting India the most. Expect non-tariff barriers. Trade off between deratings in core Europe v/s defaults in periphery could increase overall risk aversion
 - RBI policy: With little leeway left on hiking interest rates to control inflation, monetary policy moves to be muted. However, it may again get into war-mode IF there is a QE program unleashed in a few months in US or Europe
 - Govt reforms: Refer our comprehensive report "Indian Reforms: Can the govt seize this opportunity?" dt Aug 8, 2011: Items requiring approval by regulatory bodies or just Cabinet approval may move forward in the next 3 months. However, game-changing Acts requiring Parliamentary approval may take time

Recommendations

- ENAM
- High conviction bets: It is in context of this uncertain background, that we recommend our key low downside/ high absolute upside bets: RIL, Bharti, SBI, JSPL, Glenmark, Jain Irrigation, Redington, Prestige
- **Additionally**, we provide some other names for portfolio allocators and risk-takers respectively:
 - a) **Defensive hideouts** (low beta) with valuation comfort: **Coal India, Sun Pharma, PGCIL, Bajaj Auto,** Hero MotoCorp, BoB, Grasim, Cadila, Oracle, Godrej Cons, Coromandel, GSPL
 - b) Very high risk-reward bets Very high upside, with above normal risk: PFC, REC, JSW Energy, Crompton, JP Power, Suzlon, Pantaloon, Aurobindo

<u>Note</u>: Current TP upsides may not fully reflect the potential upside/ downside due to possible events. The write-ups for each stock clearly lay out the growth drivers, downside-protection, as well as the possible upsides/ risks which are beyond our current assumptions for TP.

In an uncertain world, where events keep unfolding, and <u>stock selection</u> is paramount, diving into the key upside/ downside factors has been the focus of this report – rather than being driven by TP upsides alone, which are after all, probabilistic forecasts based on today's state of things

Happy Independence Day and Raksha Bandhan!

High Conviction bets



	Mkt Cap	СМР	Target Price	Upside	P/E (x)	
Company	(USD bn)	(Rs)	(Rs)	(%)	FY12e	FY13e
Reliance Inds	55.9	773	1,155	49	10	10
Bharti Airtel	33.3	397	490	23	23	15
SBI	31.5	2,250	2,650	18	1.3	1.2
Jindal Steel & Power	10.5	512	701	37	10	9
Glenmark Pharma	2.0	331	391	18	13	14
Jain Irrigation	1.4	169	222	31	17	12
Redington India	0.8	94	128	36	13	11
Prestige Estates	0.8	114	186	63	14	11

Source: Bloomberg, ENAM Research; Note: For Banks P/E = P/B

Yes, there would be some risk in these too, as detailed in the individual stock write-ups; and hence they are not in the Defensive group - it's their ratio of upside/ downside at CMP which has secured their entry in this class

Defensives



	Mkt Cap	СМР	Target Price	Upside	P/E (x)	
Company	(USD bn)	(Rs)	(Rs)	(%)	FY12e	FY13e
Coal India	53.8	386	372	(4)	14	13
Sun Pharma	10.9	481	570	18	22	17
Power Grid	10.5	103	120	16	15	13
Bajaj Auto	9.3	1,460	1,640	12	14	13
Hero MotoCorp	8.2	1,858	1,941	4	16	14
Bank of Baroda	7.3	840	1,000	19	1.4	1.2
Grasim Inds	4.2	2,098	2,758	31	7	6
Cadila Healthcare	3.9	860	1,124	31	21	17
Oracle Financials	3.6	1,962	2,608	33	15	14
Godrej Consumer	3.0	416	475	14	24	19
Coromandel Intl	2.0	324	400	24	14	12
GSPL	1.3	101	120	19	10	10

Source: Bloomberg, ENAM Research; Note: For Banks P/E = P/B

With most defensives superbly priced, these reasonably valued stocks offer low downside, with some upside

... And for Risk-takers



	Mkt Cap	СМР	Target Price	Upside	P/E (x)	
Company	(USD bn)	(Rs)	(Rs)	(%)	FY12e	FY13e
Power Finance	5.0	173	245	42	1.1	1.0
Rural Electrification	4.1	189	240	27	1.3	1.2
JSW Energy	2.2	62	74	19	9	8
Crompton Greaves	2.0	145	224	55	12	9
JP Power Ventures	1.8	38	60	57	10	8
Suzion Energy	1.7	42	64	52	12	8
Pantaloon Retail	1.4	312	377	21	25	18
Aurobindo Pharma	1.0	155	232	50	8	7


Source: Bloomberg, ENAM Research; Note: For Financials P/E = P/B

Note: TP upsides may not factor in and reflect the entire potential

Outstanding return potential for identified above-normal risk

Table of contents





High Conviction bets

- CMP ignores E&P business completely
- **RIL to be net cash by FY12** •••
 - Led by huge operating cash flow of US\$ 7bn and US\$ 7.2bn proceeds from BP, limited capex plans in near term
- Doubling of petchem capacity in the next 2-3 years would be a huge boost to earnings
- CAG audit risk offset by BP's entry **
 - BP has already done due-diligence of the accounts of KG D6, other blocks
 - RIL's capex competitive versus global deep-water assets
- Cash allocation a risk, but management conservative enough not to destroy valuations through acquisitions
- Among most under-owned megacaps

RIL – Break-up of current market price*

	-	
(USD bn)	(Rs/ Shr)	Comments
45.7	605	FY12e EV/E of 6.5x
4.2	55	DCF
7.2	99	Does not include bonus payments of US\$ 1.8bn
5.0	66	Conversion at CMP
62.0	825	
2.5	33	net of cash from BP
59.5	792	
58.2	770	
(1.4)	(22)	E&P avibl for free
3,270		
20.5	272	
9.6	127	
7.4	98	
1.7	23	
1.8	24	
	45.7 4.2 7.2 5.0 62.0 2.5 59.5 58.2 (1.4) 3,270 20.5 9.6 7.4 1.7	4.2557.2995.06662.08252.53359.579258.2770(1.4)(22)3,2702729.61277.4981.723

Source: Company, ENAM Research * the above valuations are not our SOTP

Financial	summary								(CMP: F	≀s 773)
Y/E Mar	Sales (Rs mn)	PAT (Rsmn)	Consensus EPS* (Rs.)	EPS (Rs.)	Change (YoY %)	P/E (x)	RoE (%)	RoCE (%)	EV/EBITDA (x)	DPS (Rs)
2010	2,037,397	158,976	-	48.6	2.2	-	12.1	11.0	-	6.3
2011	2,658,110	202,110	-	61.8	27.1	-	13.5	13.2	-	7.0
2012E	2,196,604	241,720	71.8	73.9	19.6	10.5	12.7	15.3	5.1	7.0
2013E	2,158,515	251,986	80.4	77.1	4.2	10.0	10.8	13.8	4.6	7.0
Source: Compar	y, ENAM estimates;	*Consensus brok	er estimates							

Bharti Airtel



India Business

- 2G: Declining competitive intensity and recent tariff hikes to improve price realisations (RPM: Revenue Per Minute), after 3 yrs of >15% decline YoY leading to higher EBITDA margins (FY13E: ~36% vs. ~35% in FY11), cash flow generation (FY14E onwards: >USD 3 bn)
- □ **3G**/ **BWA**: 3G revs to constitute ~4% of wireless revs by FY15E and grow at >100% for next 3 yrs. Data margins higher vs. voice
- Embedded value in tower subs: Largest tower assets in the industry at ~79K towers in Q1FY12 & rising tenancy ratios. Value unlocking in tower company a key positive trigger (~25% value to target EV). Value unlocking in tower assets to enable repayment of debt undertaken for 3G/BWA/ Zain acquisition Upside if proceeds> our asspn of 12x EV/ EBITDA of FY13
- Risk: Regulatory risks with respect to Spectrum charges, Spectrum Re-farming, Towerco under licencing (total worst case TRAI-based impact at Rs 26/ share, net of licence fee reduction)

Financial summary

Africa Business

- Growth drivers: Completion of KYC compliance to stem fall in subs addns, wider network coverage to result in higher net sub adds (vs ~2 mn/ qtr currently). Margin expansion observed in past 2 qtrs (+160 bps)
- Upsides: a) possible reduction in Interconnect charges, b) improvement in operating cost/ min (our asspns of only ~150 bps/year margin expansion in next 2 years) and capex per min through outsourcing IT ops/ network, c) unlocking of African towercos
- Risk: Lower subs additions, low minutes elasticity, delay in achievement of higher margins/ operational efficiencies, interest rate risk on hi floating-rate foreign borrwgs (impact 5-7% on PBT)

(CMP: Rs 397)

Y/E Mar	Sales (Rs mn)	EBITDA (Rsmn)	PAT (Rsmn)	Consensus EPS* (Rs.)	EPS (Rs.)	Change (YoY %)	P/E (X)	RoE (%)	RoCE (%)	EV/EBITDA (x)
2010	418,472	167,633	91,638	-	24.2	8	-	24.1	23.5	-
2011	594,672	203,002	63,110	-	15.7	(35)	-	13.1	12.9	-
2012E	721,233	246,136	64,984	19.3	17.1	9	23.2	11.8	10.7	8.3
2013E	857,881	304,301	101,620	27.9	26.8	56	14.8	16.1	14.3	6.4

Source: *Consensus broker estimates, Company, ENAM estimates



- The new management team has strategically shifted from market share acquisition to incrementally focus on profitable growth. Consolidation of subsidiary banks has taken a backseat with focus on more core issues like margin expansion and recoveries
 - **Clean up:** A bold one shot step by providing for pending liabilities (pension, gratuity and NPA provisions) and cleaning up the book
 - Profitability: Management's commitment evident from withdrawal of certain low priced products (teaser rate loans) and aggressive increase in base rates (175 bps in last 6 months)
 - NPAs: Aggressive provisioning, focus on recoveries (recovery teams, tracking centers, stressed assets management group) and better risk management practices. Any large PSU exposure is more likely to be restructured
- Re-rating: Management guidance of impact on H1FY12 performance due to higher provisions already factored in, whereas the positive surprise on margins are yet be captured. Margin expansion (high 49% CASA and low 11% bulk deposits) and improving asset quality to be key re-rating triggers
- Risks: Delay in capital raising due to need for Govt's allocation to Rights may force slowdown. Rights price may be an overhang. Infra exposure ~9%, of which power is 1/3: assuming 30% of SBI's power loans go for restructuring, impact: ~4% on FY12E PBT, to factor in a 5% interest forego and 2% restructured asset provisioning

Financial	summary	(Standa	lone)	

```
(CMP: Rs 2250)
```

Y/E Mar	PAT	FDEPS	EPS Chg	P/E	P/E	Adj. BV	P/Adj. BV	P/Adj. BV	RoE	RoA	Net NPA
	(Rsmn)	(Rs)	(%)	(x)	(x)*	(Rs.)	(x)	(x)*	(%)	(%)	(%)
2010	91,661	144	0.5	15.6	10.1	929	2.4	1.7	14.8	0.9	1.7
2011	82,645	130	(9.9)	17.3	11.2	899	2.5	1.8	12.6	0.7	1.6
2012E	118,025	163	24.9	13.8	8.9	1,209	1.9	1.3	14.8	0.9	1.4
2013E	147,069	203	24.6	11.1	7.2	1,339	1.7	1.2	14.8	1.0	1.2

Source: Company, ENAM Research.*P/Adj. BV and P/E calculated after deducting value of investment from price and cost of investment from BV. We have assumed dilution of Rs 200 bn in FY12





Margin of Safety is implicit, given that JSPL's current market cap is accounted for by only operational power and steel assets. Hence, power expansion (4.4 GW), foreign coal assets (1.7 bn t), and foreign iron ore assets (20 bn t) are not in the price:

JSPL – What is the current market price factoring in*?

Segment	Value (Rs bn)	Comments
Jindal Power	184	Valued at 10x FY12 PAT + FY11 cash of Rs 22 bn
CPP - 1,350 MW	70	Valued at 10x FY13 PAT (First full yr. of operations)
Steel	219	at 5.5x FY12 EBIDTA; 1.5 MTPA expansion (vs. current 4.5 MTPA) from FY13 not considered
S. African Mine	9	Operational 50 mnt resources ; Valued at EV / reserves of USD 4/MT; with avg. GCV 6,800 Kcal/Kg & CoP USD 60/MT
Total	482	
Total (Rs/ sh)	516	
CMP (Rs/ sh)	524	

Source: Company, ENAM Research * the above valuations are not our Sum of Parts

Potential upsides: Valuation of International resources

Mine	Reserves (MT)	EV/Reserves (USD/t)	Valuation (Rs bn)	Comments
Indonesia (Coal)	500	2.0	45	Mining to commence from end FY12; ~5,000 GCV coal
Mozambique (Coal)	1,200	2.0	108	Mining to commence from FY13; ~25% coking & 75% thermal coal
Bolivia (iron ore)	20,000	-	-	Not ascribing any value as logistics challenging; co. claims to start prodn. in FY12
Total upside			153	-
Total upside (Rs/sh)			164	31% upside from CMP
Source: Company ENAM Boses	, woh			

Source: Company, ENAM Research

... JSPL



SPL's cost of production for both power & steel are in the lowest quartile of industry; hence low earnings volatility

- Dever: Fuel cost at Rs 0.5/ kWh vs. NTPC's (sector leader) fuel cost at ~Rs1.8/kWh in Q4FY11
- Steel: COP of at ~USD 450/t vs. SAIL's (sector leader) at ~USD 560/t
- Driven by volume expansion, earnings to increase by ~22% CAGR over FY11-13
 - Power: Notwithstanding an expected fall in profits from existing 1 GW capacity (due to est. fall in merchant), incremental volumes from 1,350 MW CPP (largely commercial sales initially) to drive earnings expansion, Our merchant assumptions at Rs 4.2 for FY 12 (Q1 actuals at 4.3)/ Rs 4 for FY 13 note 80% of his merchant sales are sold 12 m fwd
 - Steel: Profitability for FY12E to be driven by growth in iron ore pellet volumes (up by 2.4x to 2.2 mn MT) and the recently acquired
 Oman plant. In FY13E, earnings growth would be driven by 50% rise in steel capacity to 4.5 mn MT
- Risks: a) Draft mining Bill provisions taken in our assumptions, but could vary depending on final outcome, b) Global commodity shocks, as incremental profits in FY 12 largely from iron ore pellet sales and half of cons profits from steel where is relatively more vulnerable as an integrated player

Financial	summary									KS 512)
Y/E Mar	Sales (Rs bn)	PAT (Rs bn)	Consensus EPS* (Rs)	EPS (Rs)	Change (YoY %)	P/E (x)	RoE (%)	RoCE (%)	EV/EBITDA (x)	DPS (Rs)
2010	111	36	-	38.4	-	-	40.5	28.6	-	1.3
2011	131	38	-	40.2	-	-	30.1	22.4	-	1.5
2012E	167	47	49.0	50.3	4.7	10.2	28.2	20.5	8.0	1.9
2013E	227	53	56.7	57.0	25.2	9.0	24.8	18.7	7.4	2.5

Financial summary

(CMP: Rs 512)

Glenmark

- ENAN
- Niche product launches to drive growth in US: Has a strong portfolio of 72 products (35 ANDAs pending approval ** including 4 FTFs and 10-12 hormonal products). We estimate US business to grow at 18% CAGR over FY11-13E
- Robust domestic franchise: We expect domestic biz. to grow at 16% CAGR over FY11-13E led by increase in ••• market share in derma, CVS, respiratory & diabetic segments
- **Crofelemer launch** (first ever novel launch by any Indian company) in semi-regulated markets by 2HFY12 ** (expected to generate USD 80 mn of sales annually)
- **Base business** EPS of Rs 18 (FY 12)/21.5 (FY13) translates to a base-biz PE of 18/15, which is lower than peers **
- Upside: 6 NCEs (new chemical entity) and 2 NBEs (new biological entity) products in the R&D pipeline, with a ••• decent track record of generating revenues from out-licensing deals
- Key risks: a) Glenmark has lost a summary judgment against Abbott and Sanofi for generic Tarka and would be ** liable to pay USD 16 mn (~Rs 3/ share), however would be appealing in higher court. b) Pricing pressure in US markets

Financial s	ummary								(CMP:	Rs 331)
Y/E March	Sales (Rsmn)	PAT (Rsmn)	Consensus EPS* (Rs.)	EPS (Rs.)	Change (YoY %)	P/E (x)	RoE# (%)	RoCE (%)	EV/EBITDA (x)	DPS (Rs)
2010	24,124	3,491	-	12.9	116	-	17.6	14.5	-	0.4
2011	29,491	3,278	-	12.1	(6)	-	14.8	12.1	-	1.8
2012E	36,825	6,625	22.2	24.6	102	13.5	28.0	21.4	11.7	1.8
2013E	40,445	6,515	22.4	24.1	(2)	13.7	21.9	20.2	11.2	1.8

Jain Irrigation



Underpenetrated MIS (50% of sales, 64% of EBITDA) segment to grow at 30%+ CAGR over the next 5 years:

- **Expanding revenue avenues:** Newer states (20% of revenues in FY11) like Raj, Guj, MP and HP gaining traction
- Structural rise in farm income & cropping diversification from MSP driven crops will stimulate demand for micro irrigation
- <u>Govt initiatives in 2010:</u> (1) Recognized MIS subsidy program as a National Mission to expand addressable market & (2)
 Implementation of CWBP scheme; govt has made it obligatory to implement MIS in min 10% of canal command areas
- **Sustained growth despite rising competitive intensity**: MIS revenue grew by 31% in FY11 and 30% in Q1FY12

Improvement in capital efficiency as the government subsidy program kicks into Mission mode

- FY 11 saw states' budgets unprepared for the immediate govt thrust, and political changes, delaying subsidy payments to farmers in TN & Mah – now resolved; AP (15% of MIS revenues) still a concern
- Reduced gross receivable days in the MIS segment from 373 days in FY11 to 350 days in Q1FY12 on account of better collections. Mgmt has guided towards a further reduction in receivables to 310 days by the end of Q2FY12
- Trading below 6 yr median level: The 1-yr fw EV/EBITDA of 8x, the stock is at 25% discount to its 6 year median.
- Key Risk: Capital allocation to non MIS segments, delay in government subsidy and slower turnaround of intl. subs.

Financial	(CMP: Rs 169)									
Y/E Mar	Sales	PAT	Consensus	EPS	Change	P/E	RoE	RoCE	EV/EBITDA	DPS
	(Rsmn)	(Rsmn)	EPS* (Rs.)	(Rs.)	(YoY %)	(x)	(%)	(%)	(x)	(Rs)
2010	33,755	1,652	-	4.3	(18)	-	14.7	15.6	-	1.4
2011E	40,691	2,759	-	7.2	65	-	19.4	16.5		1.0
2012E	50,169	3,864	9.5	10.0	40	16.9	22.2	18.3	9.4	1.2
2013E	61,181	5,424	12.1	14.1	40	12.0	25.0	20.6	7.5	1.3

Redington India



- India (~47% of sales, 61% of PBIT): High growth (27% YoY) to continue in FY12E:
 - **Smart phones:** We estimate higher growth in smart phones at ~37% in FY12E and ~20% in FY13E
 - iPad: We build-in revenues for iPad at ~Rs 3.5 bn in FY12E/ Rs 10 bn in FY13E. The management places market potential at ~500K units/ Rs 20 bn opportunity (current waiting period is ~ 3 weeks), of which we assume 50% mkt share

Upsides beyond our assumptions:

- Strategic initiatives to improve working capital cycle: Higher growth in non-IT segment (Q1FY12 rev share: ~19%) and improving creditor days to improve working capital cycle. This is a long-term biz transformation (high RoE and cash flow generation). Profit sensitivity high to increasing iPad mkt share
- **Value unlocking in key ventures: (1)** NBFC (Q1FY12 book size: Rs 6.7 bn), grew ~30% YoY with zero NPAs (2) 3D PL (i.e. ADC)
- □ GST Implementation
- **Key Risks:** Further interest rate hikes, currency fluctuations for international operations

Financial summary (CMP: Rs 94							(CMP: Rs 94)		
Y/E Mar	Sales (Rs mn)	PAT (Rs mn)	Consensus EPS* (Rs.)	EPS (Rs.)	Change (YoY %)	P/E (x)	RoE (%)	RoCE (%)	EV/EBITDA (x)
2010	137,578	1,843	-	4.7	13.5	-	17.7	14.6	-
2011	174,585	2,260	-	5.7	22.6	-	20.0	16.0	-
2012E	215,114	2,840	7.3	7.2	25.7	13.1	21.9	18.0	9.0
2013E	256,563	3,390	8.8	8.6	19.4	11.0	22.2	19.0	8.1

Prestige



- Current valuations factor in value of a) OPERATIONAL rental assets (Rs 1.76 bn of annualized rental income) and b)
 Net cash flows from ONGOING development projects (Rs 43 bn over next ~3 yrs)
- Bangalore realty (~80% of portfolio): Best placed among metros
 - □ New launches from several Bangalore developers over the last quarter seeing significant absorption
 - □ Recently launched PEPL's projects saw ~1 msf being sold in the last 2 months
- Key triggers:
 - Slew of new launches: With approvals starting to come in, Prestige is expected to launch +10 msf of projects in remainder of FY12, (PEPL has maintained its sales guidance of ~Rs 15 bn for FY12 vs Rs 2.1 bn achieved in Q1FY12)
 - □ Revenue recognition boost from Q3/ Q4 as accounting thresholds being crossed
- Risks: a) Any IT slowdown, b) Cash-burn on rental and hospitality projects (but, on-going development projects and manageable incremental debt to adequately fund this)

i manolal oum	mary						(**************************************
Y/E March	Sales	PAT	EPS	RoE	RoCE	Valuation	(Rs)
	(Rs mn)	(Rs mn)	(Rs.)	(%)	(%)		
2010	10,244	1,294	3.9	13.7	10.3	Target price	186
2011	15,431	1,667	5.1	9.7	11.5	Upside (%)	63
2012E	16,313	2,763	8.4	10.9	11.6		
2013E	22,702	3,519	10.7	12.3	13.3		

Financial summary

(CMP: Rs 114)



Defensive, with valuation comfort and some upside

ENAM
It's possible!

Stock	Rationale
Coal India	Domestic coal prices at half of international prices, thus no downside if global coal prices fall. Only merchant coal miner in India and strong balance sheet (cash of ~USD 10 bn). Draft mining bill provisions already imputed in TP
	Upside if form of Bill changed to royalty-format
	Risk: wage revision above expectations
Sun Pharma	Domestic (~40% of business): 75% from robust chronic franchise
	Internatnl: Taro (27% of Sun's FY 12) boosting already strong US biz, with strong pipeline of 24 pending ANDAs
	Strong balance sheet with USD 1 bn of cash, adds scope for inorganic growth
	Upside: Caraco & Cranbury facilities getting US FDA clearance
	Risk: Pricing pressure in US mkts, any more US FDA warning letters, any liability for Protonix sales
Power Grid	A quasi monopoly where ALL costs are pass-through. Tariff structure insulated from lower PLFs due to coal shortage (take-or-pay) or stranded assets (project cluster approach)
	Risk: execution delays due to land acquisition

Defensive, with valuation comfort and some upside



Stock	Rationale
Bajaj Auto	2W defensive: high cash purchases (~65%), rural (~50%), demonstrated pricing power, not crude- sensitive
	Volume growth> industry at ~17% (sector: 12-14%) backed by new launches (Boxer, new Pulsar), strong exports
	 Consistent pricing actions and higher margin 3W (new state permits) volumes to cushion margins. Mgmt guidance of 20% to be maintained
	Risk: Govt to review DEPB (9% benefit) on 30 th Septve impact on exports (33% of volumes). Mgmt expects duty drawback scheme (replaces DEPB) to be at 4-5% and expects pricing/ absorption for the balance
Hero MotoCorp	Co's target of 6 mn units for FY12E seems intact
	Margins pressures incrementally easing, with regular price hikes
	High dividend payouts v/s competition, to continue
Bank of Baroda	Earnings growth, cost efficiencies, technological platform, asset quality consistently better than PSU peers
	100% system-based NPA recognition ensures low slippages in Q2 unlike peers
	Risk: CMD retiring in end-2012

Defensive with valuation comfort and some upside



Stock	Rationale
Grasim Inds	 VSF prices have stopped falling (45% of TP). Implied valuation of cement assets (60% stake in UltraTech) at USD 70/t vs Ultratech's current valuation at USD 120/t
	Strong net-cash balance sheet
	Upside if promoter holding increased and subsequently FII cap raised
	Risk in commodity price moves
Cadila	Domestic (~50% of business): 50% from chronic segment
Healthcare	International (~50% of business): Strong pipeline of 67 products approved by US FDA and 64 pending ANDAs
	 Upside: Launch of products from Abbott JV (26 products under JV) and faster resolution of warning letter for Moraiya facility
	Risk: Pricing pressure in US mkts
Oracle	Products (~70% of revs; ~85% of operating profit): Increased signings with Tier 1 banks
Financials	Revenue stability: AMC revs (17% of revenues, and growing), Implementation revs (~35% of revenues) which are dependent on license fee signings (recur over ~1.5-2 yrs from date of signing; FY11 saw ~25% YoY growth in license fees)
	Potential stake sale of services biz (~Rs 270/ share), strong cash reserves (~Rs 360/ share)
	Upsides: Delisting, Core banking signings, beneficiary of Dodd Frank Act implementation in FY13
	Risks: Europe exposure (~24% of products in Q1FY12), and 100% BFSI exposure

Defensive with valuation comfort and some upside



Stock	Rationale
Godrej Consumer	 64% of revenues is still India-centric, showing firm growth in all 3 categories Softening commodity costs and calibrated price hikes will aid margins in 2HFY12 Upside: Earnings surprise from Darling acquisition, cost rationalization due to integration
Coromandel Intl	 25% fertilizer volume growth by 2HFY13, increase in profitability from non-subsidy business (20% of PBIT, to grow to 40% in ~3 yrs) Upside: Increase in complex fertilizer consumption, post urea de-regulation in Oct Risk: As DAP prices rise, if Govt maintains NBS subsidy rates (based on \$612/ t vs spot of 670), margins may reduce – Govt has kept increasing subsidies to avoid shortage
GSPL	 Current pipelines valued at 1.8x FY12 P/BV reasonable, given fixed 12% post-tax RoCE return New pipelines to generate value in long term as absence of domestic gas finds necessitates significant LNG capacity to come online in next 5-6 years Upside: Improved visibility in gas supplies through announcements of LNG terminal or huge domestic gas finds Risk: Reduction in tariffs on existing Gujarat pipelines, cost over-runs in new pipelines

Very high risk-reward bets!

SEB Reforms



The SEB situation is alarming, with losses mounting to ~USD 15 bn. Five states (UP, MP, TN, Raj and Har) contribute ~65-70% of losses. Financial health of SEBs has caused collateral damage to gencos through off-take risk (questioning SEBs' ability to pay its dues and procure relatively expensive merchant/imported coal power). This impacts lenders such as REC & PFC (deferrals expected from SEBs and gencos). A bailout package by central government or default by the SEBs seems highly unlikely

Key provisions:

- The state governments may consider converting loans due from the state governments to the distribution utilities as government equity to ensure capital infusion and improve the net worth of the utility
- Allow SEBs to increase tariff annually and State governments to ensure that distribution utilities file their Annual Tariff Revision Petition every year and also get their account audited periodically. Watch-out for tariff increases by TN during H2FY12.
- Introduction of rating mechanism for SEBs in the next 6 months to enforce greater financial discipline amongst SEBs
- **Timely disbursement of subsidies to state electricity boards by the respective state governments.**
- Appointing distribution franchises in urban areas through competitive bidding i.e. privatization of distribution circles.

Beneficiaries:

 If the above recommendations are implemented, it would improve SEB financials structurally, thereby improving outlook on Power financiers – REC and PFC.

Very high risk-reward bets! : Power Financing



Stock	Rationale/ Upside	Risks/ Downside
PFC	 Strong growth visibility: outstanding sanctions at ~1.7x total loan assets Maintains healthy asset quality with Net NPA ratio at 0.20%. Expected SEB reforms to abate asset quality concerns, a key re-rating trigger Maintains margins at healthy level (~3.9%). With assets getting repriced in coming quarters, margins are expected to remain stable Maintains adequate safeguards such as escrow mechanism, sufficient government guarantee and asset charge to protect its asset quality 	 Any significant delay in implementation of SEB reforms may lead to increased uncertainty on asset quality Significant increase in interest rate may impact its growth rates with few projects becoming unviable Exposure to imported coal UMPPs where tariffs inadequate
REC	 Improvement in lending mix, with increase in share of generation segment (to ~43%) will strengthen its balance sheet Private sector contribution is expected to increase to ~13.5% by FY12E (currently at 11%) which will support margins Maintains healthy return ratios with expected ROE of ~22% and ROA of ~3% in FY12E and strong growth visibility Maintains 0.26% Net NPA ratio. SEB reforms which are expected in some time will abate the asset quality risks 	 Significant increase in interest rate may impact its growth rates with few projects becoming unviable Currently maintains ~50% of its loan book in T&D segment which is more susceptible to asset quality risk Un-hedged foreign borrowing may lead to some MTM losses due to Fx variation. ~11% of its borrowing is in form of foreign currency borrowing of which >70% is hedged

Very high risk-reward bets! : Power Utilities



Stock	Rationale/ Upside	Risks/ Downside
JP Power	 Limited downside as CMP= 3 operational hydro assets of 1.7 GW Current upside of 60% is largely derived from the underconstruction 1.3 GW on domestic captive mines (no forest & land issues) with expected CoD in Q1FY14 Further upside if the on-going tariff negotiation for the recently commissioned 1 GW hydro is favorable, with higher proportion of merchant vs. current at 20% 	 High leverage at D:E of 2.6x Equity dilution required for projects beyond 3.5 GW High leverage at the parent level (JP Associates)
JSW Energy	 Limited downside: CMP= operational assets of 3.1 GW at current replacement cost of Rs 55 mn/MW. CMP also implies coal prices at USD 130 for perpetuity and merchant at Rs 3.5/kWh Sustainability: NOT in question due to low leverage (D:E) of 1.4x and positive cash-flows considering above assumptions Current upside of 30%+ could improve: a) Forthcoming projects (2.9 GW) on domestic captive blocks: land acquisition and eqpt ordering process is on, b) SEB reforms could improve merchant outlook (current asspns @ Rs 4) 	 Higher imported coal spot prices High sensitivity to merchant prices and continued distress in SEBs financials may impact merchant realization as well as the receivable cycle negatively

Very high risk-reward bets! : Power Equipment...



Stock	Rationale/ Upside	Risks/ Downside
Suzion Energy	 With 100% of REpower a mere formality, Suzlon now has access to its cash flows and superior technology REpower is one of the global leaders in 2 MW on-shore products, which is the dominant volume segment in on-shore. Also a global leader in 5/6 MW high-margin hyper-growth offshore segment. However, European manufacturing base were high cost, restricting its volumes to only Europe On-shore: Can compete better in India and Europe, with tech+ cost advantage due to manufacturing REpower now in India Offshore: Germany (world's 2nd largest mkt) has closed further nuclear plants - REpower gets home-mkt advantage Indian wind mkt (Suzlon has 50% mkt share) doubled to ~3GW, as cost of power thru wind now= imported coal based plants. Suzlon's PBT break-even is at 1.7 GW, which is now near-guaranteed from India alone FCCB repayment of Rs 25 bn in FY13 now manageable: cash of ~Rs 20 bn (REpower), Rs 7 bn (Hansen sale) & ~Rs 10 bn (overdue receivables) 	 Recently, global majors such as Siemens & Emerson have issued order-inflow growth warning. REpower (~60% of FY13E PAT) derives majority of its sales from Europe and may face deferrals, as witnessed during 2008 Above impact on REpower can be more as it is expanding capacities & manpower Any collapse in oil/ coal prices to affect relative economics of wind power

Very high risk-reward bets! : ...Power Equipment



Stock	Rationale/ Upside	Risks/ Downside
Crompton Greaves	 International Subs: In Q1, loss at EBITDA level was circumstantial due to deferral of revenue of ~20% of Q1FY12 sales. Expect sustainable sales growth of 6-7% & margins of 6-8% Domestic T&D and Industrial biz: ABB & Siemens' domestic T&D and industrial biz are 2.5x larger than CG, largely due to technology advantage in automation. CG has now bridged this through acquisitions. In FY 13, PGCIL to bring in compulsory domestic sourcing Risk/ reward: Considering normalized international subs margins of ~8% and pick-up in domestic T&D, expect EPS of Rs 16 in FY13 & RoE of 20%+. Favorable risk-reward at P/E of 9xFY13 	 International biz (30% of EBITDA) could face risk of project deferral due to European debt crisis. Further, global majors such as Siemens, Emerson, etc have issued order inflow growth warning T&D Order flows from PGCIL and state transmission Cos. do not pick-up in FY12

Very high risk-reward bets! : Others



Stock	Rationale/ Upside	Risks/ Downside
Pantaloon	 FDI for multi-brand retailing could entail strategic tie-up with MNC retailers, with additional funds: Will improve balance sheet, enhance supply chain efficiency & accelerate growth plans for hypermarket food & grocery retailing Our sensitivity analysis for 25 to 45% stake sale in FVRL indicates a potential 57% to 114% upside to FY13E earnings (assuming stake sale at 1x EV/S to enter growth mkt) 	 Rising interest cost and a stretched balance sheet (D/E at 1.4x) could strain operating cash flow and thereby growth in FY12 Same-store sales impacted by increase in apparel prices and decline in consumer sentiments
Aurobindo	 US biz. (27% of FY11 sales) to lead growth @ 15%+ CAGR over FY11-13E: Strong product pipeline (215 cumulative and 77 ANDAs pending approval) in US EU/RoW biz. (12% of FY11 sales) growth at 24% CAGR over FY11-13E, to be led by product launches, geographic expansion and supply to Pfizer/ AstraZeneca Thus formulations' contribution to sales would rise from 54% in FY11 to 65%+ in FY13E. EBITDA margin (ex-dossier income) expansion from 17% in FY11 to 19% in FY13E 	 Unit-VI (~3% contribution to FY11 sales) is currently under Import Alert and Unit-III (8-10% contribution to FY11 sales) is under Warning Letter from US FDA. Delay in resolution could slow down approval process and hamper future growth. Also, corrective action cost may impact margins High dependency on Pfizer – Change of focus by Pfizer/ inability to launch products/ garner market share would impact revenues

ENAM Securities Pvt. Ltd.

7, Tulsiani Chambers, Free Press Journal Marg, Nariman Point, Mumbai – 400 021, India.. **Tel:- Board** +91-22 6754 7600; **Dealing** +91-22 2280 0167; **Fax:- Research** +91-22 6754 7679; **Dealing** +91-22 6754 7575

This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Nothing in this document should be construed as investment or financial advice, and nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. The intent of this document is not in recommendary nature

Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors

Enam Securities Private Limited has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval

Enam securities Private Limited, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document

This report has been prepared on the basis of information, which is already available in publicly accessible media or developed through analysis of ENAM Securities Private Limited. The views expressed are those of analyst and the Company may or may not subscribe to all the views expressed therein

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S.Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions

Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

Copyright in this document vests exclusively with ENAM Securities Private Limited.